EMP2 and non-small cell lung carcinoma: After treatment with a DNA methyltransferase inhibitor, 5-aza-2′-deoxycytidine (DAC), EMP1 mRNA expression markedly increased in three NSCLC cell lines, including H2170, H23, and A549 (Figure S1), while EMP2 mRNA was enhanced in six NSCLC cell lines, namely, H2170, H1299, H226, H2030, A549, and H1650 (Figure S2).